Full text
PDF

Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982 Jan-Feb;7(1):1–22. doi: 10.2165/00003088-198207010-00001. [DOI] [PubMed] [Google Scholar]
- Eichelbaum M., Reetz K. P., Schmidt E. K., Zekorn C. The genetic polymorphism of sparteine metabolism. Xenobiotica. 1986 May;16(5):465–481. doi: 10.3109/00498258609050252. [DOI] [PubMed] [Google Scholar]
- Ishizaki T., Eichelbaum M., Horai Y., Hashimoto K., Chiba K., Dengler H. J. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol. 1987 Apr;23(4):482–485. doi: 10.1111/j.1365-2125.1987.tb03080.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982 Sep-Oct;7(5):373–400. doi: 10.2165/00003088-198207050-00001. [DOI] [PubMed] [Google Scholar]
- Lou Y. C., Ying L., Bertilsson L., Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. 1987 Oct 10;2(8563):852–853. doi: 10.1016/s0140-6736(87)91034-8. [DOI] [PubMed] [Google Scholar]
- McGourty J. C., Silas J. H., Lennard M. S., Tucker G. T., Woods H. F. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol. 1985 Dec;20(6):555–566. doi: 10.1111/j.1365-2125.1985.tb05112.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
